Heidelberg, Germany, April 2, 2020 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on its operations in response to the continued spread of the COVID-19 coronavirus pandemic. Affimed also announced that it will host a conference call on Tuesday, April 28, 2020 at 8:30 a.m. ET to discuss its full year 2019 financial results and recent corporate developments. `Our priority at this time is to ensure the safety and health of our employees, their families, our partners and the patients we serve, while also maintaining continuity of our business and ongoing clinical trials,`...
|
